I-Mab Biopharma (IMAB) Tops Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMAB Hot Sheet
Join SI Premium – FREE
I-Mab Biopharma (NASDAQ: IMAB) reported Q2 EPS of ($0.09), $0.22 better than the analyst estimate of ($0.31).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Active options: META RIOT PLTR CRWV NFLX SMCI SOFI GOOG IREN HOOD
- SMX -- Good Intentions Don't Count; Measured Plastic Does
- VivoPower posts $6.8M revenue and $0.6M profit in Q1 FY2027
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
